lack of efficacy
Barbara Gehrett, MD; Joseph Gehrett, MD; Chris Flowers, MD; and Loree Britt

Report 88: 2.5 Months After COVID Vaccine Rollout, Pfizer Changed Criteria for ‘Vaccination Failure,’ Causing 99% of Reported Cases to Not Meet That Definition. 3.9% of Reported ‘Lack of Efficacy’ Cases Ended in Death in First 90 Days of Public Vaccine Availability.

The War Room/DailyClout Pfizer Documents Analysis Project Post-Marketing Group (Team 1) – Barbara Gehrett, MD; Joseph Gehrett, MD; Chris Flowers, MD; and Loree Britt – penned a telling analysis of the “Vaccine Effectiveness” Safety Concern section found in Pfizer document 5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 […]

Pfizer COVID vaccine
Lora Hammill BSMT, ASCP; David Shaw; Chris Flowers M.D.; Loree Britt; Joseph Gehrett M.D.; Barbara Gehrett M.D.; Michelle Cibelli RN, BSN; Margaret Turoski, RPh; Cassie B. Papillon; and Tony Damian

Report 87: In Early 2021, Pfizer Documented Significant Harms and Deaths Following Vaccination with Its mRNA COVID Vaccine. The FDA Did Not Inform the Public.

INTRODUCTION “5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162b2) Received Through 28-Feb-2021,” Pfizer’s post-marketing report, a required U.S. Food and Drug Administration (FDA) compliance document, is one of the ways in which the FDA assessed patients’ risks associated with Pfizer’s COVID-19 vaccine, BNT162b2. The data within the […]

pfizer
Robert W. Chandler, MD, MBA

Report 03: Phase 1 /2 Study of COVID-19 RNA Vaccine BNT162b1 in Adults: Key Processes Missing.

Mulligan, Lyke et al. Nature Published online August 12, 2020. Cite this article as: Mulligan, M. J. et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature https://doi.org/10.1038/s41586-020-2639-4 (2020).   P1 p2: The authors’ put forth the argument that mRNA in BNT162b1 (Note this series used BNT162b1 […]